SCHEMBL336889

SCHEMBL336889

CCOC(=O)CC(=O)N(C)c1nc(-c2ccccc2)cnc1C(=O)OC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.46
RAB9A P51151 4/20 0.46
ALDH1A1 P00352 11/20 0.44
SMN1; SMN2 Q16637 6/20 0.44
HTT P42858 1/20 0.41
MAPT P10636 4/20 0.41
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
GLA P06280 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
KDM4E B2RXH2 6/20 0.40
HPGD P15428 6/20 0.40
HSD17B10 Q99714 3/20 0.40
LMNA P02545 3/20 0.40
GAA P10253 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
PARP1 P09874 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
GSTO1 P78417 1/20 0.39
SQOR Q9Y6N5 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL337769 0.80 ALDH1A1 (0.43) NPC1RAB9AALDH1A1SMN1; SMN2KDM4E
SCHEMBL13629341 0.71 IKBKB (0.46) NPC1RAB9AALDH1A1SMN1; SMN2MAPT
SCHEMBL7965215 0.71 NPC1 (0.58) NPC1RAB9AALDH1A1SMN1; SMN2MAPT
SCHEMBL6057019 0.71 PDCD1 (0.48) NPC1RAB9AALDH1A1SMN1; SMN2MAPT
SCHEMBL336653 0.71 ATR (0.53) ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10
SCHEMBL336700 0.70 SMN1; SMN2 (0.48) NPC1RAB9AALDH1A1SMN1; SMN2MAPT
SCHEMBL221624 0.69 MEN1 (0.46) NPC1RAB9AALDH1A1SMN1; SMN2MAPT
SCHEMBL3461817 0.69 IKBKB (0.49) NPC1RAB9AALDH1A1SMN1; SMN2MAPT
SCHEMBL3462566 0.69 ATR (0.66) ATM
SCHEMBL8472209 0.68 SMN1; SMN2 (0.54) NPC1RAB9AALDH1A1SMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097620-B2 Diazaquinolones that inhibit prolyl hydroxylase activity AMGEN INC. (US) 2012-01-17 US disclosed
EP-2155746-A2 DIAZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY Amgen, Inc (US) 2010-02-24 EP disclosed
US-20090099171-A1 Diazaquinolones that inhibit prolyl hydroxylase activity AMGEN INC. (US) 2009-04-16 US disclosed
WO-2008137084-A2 DIAZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY AMGEN INC. (US) 2008-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099171-A1 Diazaquinolones that inhibit prolyl hydroxylase activity EGLN3, EGLN2, HIF1AN NPC1 2072/4885RAB9A 3899/4885ALDH1A1 108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.